Cybin Inc. , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce.
Imugene Ltd (ASX:IMU, OTC:IUGNF) has received a valuation of A$2.98 billion or A$0.48 per share in initial coverage by Diamond Equity Research. The analyst.
iBio, Inc (IBIO) Acquires RubrYc Therapeutics AI Drug Discovery Platform and Pipeline streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Highlights: APIRx has twenty-two (22) active clinical and pre-clinical research and development projects therapeutic candidates are targeted at treating pain,.